SCEMBLIX

This brand name is authorized in Australia, Canada, France, Israel, Japan, Lithuania, Romania, United Kingdom, United States

Active ingredients

The drug SCEMBLIX contains one active pharmaceutical ingredient (API):

1 Asciminib UNII C5U34S9XFV - ASCIMINIB HYDROCHLORIDE

Asciminib is a potent inhibitor of ABL/BCR::ABL1 tyrosine kinase. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein by specifically targeting the ABL myristoyl pocket. Read about Asciminib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SCEMBLIX Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EA06		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EA BCR-ABL tyrosine kinase inhibitors
Discover more medicines within L01EA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02528320, 02528339
Country: FR	Base de données publique des médicaments	Identifier(s): 65990614, 67826243
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9247, 9248
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291077F1027, 4291077F2023
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095412, 1095413, 1095414, 1095415
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69170001, W69170002, W69171001, W69171002
Country: US	FDA, National Drug Code	Identifier(s): 0078-1091, 0078-1098